发布求助
文献互助 智能选刊 最新文献

Topics in antiviral medicine最新文献

筛选
英文 中文
Approaching monkeypox: a guide for clinicians. 应对猴痘：临床医生指南。
Topics in antiviral medicine Pub Date : 2022-10-01
Heidi M Torres, Grant Ellsworth, Jason Zucker, Marshall J Glesby
{"title":"Approaching monkeypox: a guide for clinicians.","authors":"Heidi M Torres, Grant Ellsworth, Jason Zucker, Marshall J Glesby","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 2022 outbreak of monkeypox virus infection has expanded far beyond regions in which the disease was previously endemic. Monkeypox has a wide range of manifestations, some of which are unique to this outbreak. Novel clinical presentations, testing limitations, and a lack of available treatments have contributed to delays in recognition, diagnosis, and treatment of monkeypox. As health care workers and governments fight this rare viral infection, which may become a routine diagnosis, early recognition of potential signs and symptoms along with appropriate testing is essential to prevent continuing spread and potential endemicity.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"30 4","pages":"575-581"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681140/pdf/tam-30-575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9850919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing depressive disorders among people with HIV. 解决艾滋病毒感染者的抑郁障碍。
Topics in antiviral medicine Pub Date : 2022-04-01
Andres Fuenmayor, Francine Cournos
{"title":"Addressing depressive disorders among people with HIV.","authors":"Andres Fuenmayor, Francine Cournos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Depressive disorders are the most common psychiatric disorders among people with HIV. Depressive disorders cause great suffering and disability and, among people with HIV, are associated with numerous negative HIV outcomes, including nonadherence to antiretroviral medication and increased morbidity and mortality. This article is focused on the detection, differential diagnosis, and management of depressive disorders among adults in HIV primary care settings in the United States. Because of the siloed nature of HIV primary health care and behavioral health care in the United States, this paper is geared toward clinicians who are not behavioral health specialists and who are working in HIV care settings that have limited access to behavioral health services and still seek to treat depressive disorders. In clinical settings that are fortunate enough to have well-integrated behavioral health services, HIV primary care clinicians may be able to depend on this specialist workforce, but these settings tend to be the exception and not the rule.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"30 2","pages":"454-463"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306689/pdf/tam-30-454.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40451697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on tuberculosis/HIV coinfections: across the spectrum from latent infection through drug-susceptible and drug-resistant disease. 关于结核病/艾滋病毒合并感染的最新情况:从潜伏感染到药物敏感和耐药疾病的整个范围。
Topics in antiviral medicine Pub Date : 2022-04-01
Elisa H Ignatious, Susan Swindells
{"title":"Update on tuberculosis/HIV coinfections: across the spectrum from latent infection through drug-susceptible and drug-resistant disease.","authors":"Elisa H Ignatious,&nbsp;Susan Swindells","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tuberculosis (TB) remains the leading cause of death among people with HIV, and annual risk of progression from latent TB infection to active disease in this population is 10%. Diagnostic tests for latent and active TB remain suboptimal for people with HIV who have a CD4+ count below 200 cells/μL, and there is an urgent need for assays that predict progression from latent to active disease, monitor treatment response, and test for cure after latent and active TB treatment. Traditional treatment duration for latent infection and active TB disease has been onerous for patients; however, shorter-course regimens are increasingly available across the spectrum of TB, including for drug-resistant TB. Simultaneous treatment of HIV and TB is complicated by drug-drug interactions, although trials are ongoing to better understand the magnitude of these interactions and guide clinicians in how to use short-course regimens, particularly for people with HIV.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"30 2","pages":"464-472"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306687/pdf/tam-30-464.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40451698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CROI 2022: epidemiologic trends and prevention for HIV and SARS-CoV-2. CROI 2022:艾滋病毒和SARS-CoV-2的流行趋势和预防。
Topics in antiviral medicine Pub Date : 2022-04-01
Susan Buchbinder, Albert Liu
{"title":"CROI 2022: epidemiologic trends and prevention for HIV and SARS-CoV-2.","authors":"Susan Buchbinder,&nbsp;Albert Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>At the 2022 Conference on Retroviruses and Opportunistic Infections, several speakers discussed disparities in HIV and COVID-19 infections and outcomes. Although the lifetime risk of HIV infection in the United States is higher overall in males than females, Black females have higher risk than White males. In 12 countries in sub-Saharan Africa, women aged 15 to 34 years accounted for more than half of all infections. Because knowledge of HIV serostatus is important for treatment and for prevention, several novel strategies were evaluated in the distribution of HIV self-test kits to undertested populations in the United States and sub-Saharan Africa. Data were presented on new products in the pre-exposure prophylaxis (PrEP) pipeline, including long-acting injectable cabotegravir, islatravir, vaginal rings, and in-situ forming implants. Challenges remain in the rollout of oral PrEP, and a number of innovative strategies to address barriers were discussed. Models suggest that the greatest impact of novel PrEP agents would be to increase the pool of persons using PrEP, rather than through improved efficacy. COVID-19 caused substantial declines in HIV and sexually transmitted infection prevention and treatment services, which have started to rebound, but are not yet at prepandemic levels in several settings.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"30 2","pages":"426-453"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306688/pdf/tam-30-426.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40451696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CROI 2022: summary of basic science research in HIV and SARS-CoV-2. CROI 2022: HIV和SARS-CoV-2基础科学研究综述。
Topics in antiviral medicine Pub Date : 2022-04-01
Mario Stevenson
{"title":"CROI 2022: summary of basic science research in HIV and SARS-CoV-2.","authors":"Mario Stevenson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Conference on Retroviruses and Opportunistic Infections (CROI) 2022, which was held as a virtual conference, continues to serve as the preeminent forum that features research advances in HIV-1 and its associated coinfections. The conference has extended its area of coverage to include research advances in SARS- CoV-2. As pointed out in the presentation from Hatziioannou in the New Investigators workshop, there has been an explosion in research activity on SARS-CoV-2 that has eclipsed that for HIV-1. In the past 12 months, there were approximately 6600 publications on HIV-1 and approximately 64,000 on SARS-CoV-2. Although these numbers include review articles, they reveal the tremendous response by researchers to the existential threats posed by lentiviruses and coronaviruses. This poses challenges for any conference committee tasked with selecting abstracts for presentation from the large number submitted for consideration. CROI organizers have consistently been able to assemble a program that, through invited presentations, abstract-driven talks, posters, interactive sessions, workshops, and symposia, showcases the most recent research advances.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"30 2","pages":"419-425"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306690/pdf/tam-30-419.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40451695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The changing impact of vaccines in the COVID-19 pandemic 疫苗在COVID-19大流行中不断变化的影响
Topics in antiviral medicine Pub Date : 2022-03-13 DOI: 10.1101/2022.03.10.22272222
J. A. Cohen, R. Stuart, J. Panovska-Griffiths, E. Mudimu, R. Abeysuriya, C. Kerr, M. Famulare, D. Klein
{"title":"The changing impact of vaccines in the COVID-19 pandemic","authors":"J. A. Cohen, R. Stuart, J. Panovska-Griffiths, E. Mudimu, R. Abeysuriya, C. Kerr, M. Famulare, D. Klein","doi":"10.1101/2022.03.10.22272222","DOIUrl":"https://doi.org/10.1101/2022.03.10.22272222","url":null,"abstract":"The Omicron wave has left a global imprinting of immunity which changes the COVID landscape. In this study, we simulate six hypothetical variants emerging over the next year and evaluate the impact of existing and improved vaccines. We base our study on South Africa's infection- and vaccination-derived immunity. Our findings illustrate that variant-chasing vaccines will only add value above existing vaccines in the setting where a variant emerges if we can shorten the window between variant introduction and vaccine deployment to under three weeks, an impossible time-frame without significant NPI use. This strategy may have global utility, depending on the rate of spread from setting to setting. Broadly neutralizing and durable next-generation vaccines could avert over three-times as many deaths from an immune-evading variant compared to existing vaccines. Our results suggest it is crucial to develop next-generation vaccines and redress inequities in vaccine distribution to tackle future emerging variants.","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90507945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Tenofovir Disoproxil Fumarate and severity of COVID-19 in people with HIV infection 富马酸替诺福韦与艾滋病毒感染者的COVID-19严重程度
Topics in antiviral medicine Pub Date : 2021-11-11 DOI: 10.1101/2021.11.11.21266189
J. delAmo, Rosa Polo, Santiago Moreno, Esteban Martinez, A. Cabello, J. Iribarren, Adrià Curran, J. Macias, Marta Montero, Carlos Dueñas, Ana I Marino, Santiago Perez de la Camara, Asuncion Diaz, Jose R Arribas, I. Jarrín, Miguel A. Hernán, -. T. C. C. I. Spain
{"title":"Tenofovir Disoproxil Fumarate and severity of COVID-19 in people with HIV infection","authors":"J. delAmo, Rosa Polo, Santiago Moreno, Esteban Martinez, A. Cabello, J. Iribarren, Adrià Curran, J. Macias, Marta Montero, Carlos Dueñas, Ana I Marino, Santiago Perez de la Camara, Asuncion Diaz, Jose R Arribas, I. Jarrín, Miguel A. Hernán, -. T. C. C. I. Spain","doi":"10.1101/2021.11.11.21266189","DOIUrl":"https://doi.org/10.1101/2021.11.11.21266189","url":null,"abstract":"Effective, safe, and affordable antivirals are needed for COVID-19. Tenofovir has not been studied in randomized trials despite evidence consistent with its effectiveness against COVID-19.We studied HIV-positive individuals on antiretroviral therapy (ART) in 2020 at 69 HIV clinics in Spain. We collected data on sociodemographics, ART, CD4-cell count, HIV-RNA viral load, comorbidities and the following outcomes: laboratory-confirmed SARS-CoV-2 infection, COVID-19 hospitalization, intensive care unit (ICU) admission and death. We compared the 48-week risks for individuals receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/ FTC, abacavir (ABC)/lamivudine (3TC), and other regimes. All estimates were adjusted for clinical and sociodemographic characteristics via inverse probability weighting.Of 51,558 eligible individuals, 39.6% were on TAF/FTC, 11.9% on TDF/FTC, 26.6% on ABC/3TC, 21.8% on other regimes. There were 2,402 documented SARS-CoV-2 infections (425 hospitalizations, 45 ICU admissions, 37 deaths). Compared with TAF/FTC, the estimated risk ratios (RR) (95% CI) of hospitalization were 0.66 (0.43, 0.91) for TDF/FTC and 1.29 (1.02, 1.58) for ABC/3TC, the RRs of ICU admission were 0.28 (0.11, 0.90) for TDF/FTC and 1.39 (0.70, 2.80) for ABC/3TC, and the RRs of death were 0.37 (0.23, 1.90) for TDF/FTC and 2.02 (0.88-6.12) for ABC/3TC. The corresponding RRs of hospitalization for TDF/FTC were 0.49 (0.24, 0.81) in individuals ≥50 years and 1.15 (0.59, 1.93) in younger individuals.Our findings suggest that, compared with other antiretrovirals, TDF/FTC lowers COVID-19 severity among HIV-positive individuals with virological control. This protective effect may be restricted to individuals aged 50 years and older.","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84128282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial 模拟瑞德西韦对COVID-19住院患者的随机、对照、开放标签DisCoVeRy试验的抗病毒疗效
Topics in antiviral medicine Pub Date : 2021-10-20 DOI: 10.1101/2021.10.19.21265209
G. Lingas, N. Néant, A. Gaymard, D. Belhadi, G. Peytavin, M. Hites, T. Staub, R. Greil, J. Paiva, J. Poissy, N. Peiffer‐Smadja, D. Costagliola, Y. Yazdanpanah, F. Wallet, A. Gagneux-Brunon, F. Mentré, F. Ader, C. Burdet, J. Guedj, M. Bouscambert-Duchamp, DisCoVeRy study group
{"title":"Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial","authors":"G. Lingas, N. Néant, A. Gaymard, D. Belhadi, G. Peytavin, M. Hites, T. Staub, R. Greil, J. Paiva, J. Poissy, N. Peiffer‐Smadja, D. Costagliola, Y. Yazdanpanah, F. Wallet, A. Gagneux-Brunon, F. Mentré, F. Ader, C. Burdet, J. Guedj, M. Bouscambert-Duchamp, DisCoVeRy study group","doi":"10.1101/2021.10.19.21265209","DOIUrl":"https://doi.org/10.1101/2021.10.19.21265209","url":null,"abstract":"Despite several clinical studies, the antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial. We analyzed nasopharyngeal normalized viral loads collected in the 29 days following randomization from 665 hospitalized patients included in the DisCoVeRy trial, allocated to either standard of care (SoC, N=329) or SoC + remdesivir for 10 days (N=336). We used a mathematical model to reconstruct viral kinetic profiles and estimate the antiviral efficacy of remdesivir in reducing viral production. To identify factors associated with viral kinetics, additional analyses were conducted stratified either on time of treatment initiation ([≤] or > 7 days since symptom onset) or viral load at randomization (< or [≥] 3.5 log10 copies/104 cells). In our model, remdesivir reduced viral production by 2-fold on average (95%CI: 1.5-3.2). Using the estimated parameter of the model, simulations predict that remdesivir reduces time to viral clearance by 0.7 day compared to SoC, with large inter-individual variabilities (Inter-Quartile Range, IQR: 0.0-1.3 days). Exploratory analyses suggest that remdesivir had a larger impact in patients with a high viral load at randomization, reducing viral production by 5-fold on average (95%CI: 2.8-25), leading to a predicted median reduction in the time to viral clearance of 2.4 days (IQR: 0.9-4.5 days). In summary, our model shows that remdesivir reduces viral production from infected cells by a factor 2, leading to a median reduction of 0.7 days in the time to viral clearance compared to SoC. The efficacy was larger in patients with high level of viral load at treatment initiation.","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"85 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81228976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV and Cardiovascular Disease: From Insights to Interventions. 艾滋病毒和心血管疾病:从见解到干预。
Topics in antiviral medicine Pub Date : 2021-10-01
Matthew J Feinstein
{"title":"HIV and Cardiovascular Disease: From Insights to Interventions.","authors":"Matthew J Feinstein","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Individuals with HIV have elevated risks for cardiovascular diseases (CVDs) ranging from myocardial infarction to heart failure. Our understanding of this heightened HIV-associated cardiovascular risk has evolved over the past 2 decades. In the early era of antiretroviral therapy (ART), concern existed that ART was the primary driver of cardiovascular risk. However, it has become increasingly apparent that HIV-related viremia, immune dysregulation, and inflammation are primary drivers of HIV-associated cardiovascular risk, along with traditional cardiovascular risk factors such as tobacco smoking. Indeed, early and effective ART blunts risk for CVDs among individuals with HIV. Despite these improvements in HIV-associated cardiovascular risk, questions remain regarding how to optimally predict, prevent, and treat CVDs among individuals with HIV. Efforts are underway to define more precisely which diagnostic and therapeutic strategies will be most effective in curbing HIV-associated CVDs.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"29 4","pages":"407-411"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670825/pdf/tam-29-407.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39798065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and Opportunities for Preexposure Prophylaxis. 暴露前预防的挑战和机遇。
Topics in antiviral medicine Pub Date : 2021-10-01
Mary Catherine Cambou, Raphael J Landovitz
{"title":"Challenges and Opportunities for Preexposure Prophylaxis.","authors":"Mary Catherine Cambou,&nbsp;Raphael J Landovitz","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite major advances in the HIV prevention toolbox in the past decade, there remain substantial social, economic, and structural barriers to access to preexposure prophylaxis (PrEP) that prevent a universal, population-level reduction in HIV incidence. Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) has been the flagship PrEP regimen, and data support a pericoital/on-demand \"2-1-1\" dosing schedule for men who have sex with men. Daily oral PrEP with tenofovir alafenamide combined with emtricitabine (TAF/FTC) was approved by the US Food and Drug Administration (FDA) in 2019 for all routes of exposure other than vaginal exposures. The effectiveness of daily oral TDF/FTC has not been consistent in cisgender women outside of serodifferent couples, likely owing to differences in vaginal tissue penetration of PrEP agents resulting in less \"forgiveness\" of nonadherence. These observations have highlighted the need for additional choices of HIV prevention strategies. Injectable long-acting cabotegravir was recently shown to be superior to daily oral TDF/FTC across risk populations. PrEP studies of islatravir are underway for a monthly oral formulation and a drug-eluting subdermal implant. Lenacapavir, with a novel mechanism of action, is under investigation as a subcutaneous injection at 6-month intervals.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"29 4","pages":"399-406"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670824/pdf/tam-29-399.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39952918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书